

Effect of miR-449a-mediated Notch signaling pathway on the proliferation, apoptosis and invasion of papillary thyroid carcinoma cells

YUJIE HOU¹, FEILING FENG² and RONGHUA YANG³

¹Department of Endocrinology, Second People's Hospital of Guilin, Guilin, Guangxi Zhuang Autonomous Region 541002; ²Department of Pathophysiology, Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region 541001; ³Department of Internal Medicine, Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region 541002, P.R. China

Received June 2, 2019; Accepted November 15, 2019

DOI: 10.3892/or.2019.7443

Abstract. The present study aimed to investigate the effect of miR-449a-mediated Notch signaling pathway on the proliferation, apoptosis and invasion of papillary thyroid carcinoma cells. Human papillary thyroid carcinoma cell line TPC-1 was selected, and cells were grouped and transfected: Control group (without any treatment), negative control (NC) group (transfection with NC plasmid), miR-449a mimic group (transfection with miR-449a mimic), miR-449a inhibitor group (transfection with miR-449a inhibitor), DAPT group (addition of γ -secretase inhibitor DAPT to inhibit the Notch signaling pathway), and miR-449a inhibitor + DAPT group (transfection with miR-449a inhibitor and addition of DAPT). The target relationship between miR-449a and Notch1 was detected by dual-luciferase reporter assay. qRT-PCR and western blotting were used to assess the expression of miR-449a, Notch1 and Jagged1 in cells. Cell proliferation was detected using EdU; the cell cycle and apoptosis were detected by flow cytometry; cell invasion ability was detected by Transwell assay. PCNA, MMP-2, MMP-9, Bcl-2 and Bax mRNA and protein expression were assessed by qRT-PCR and western blotting. The results revealed that miR-449a negatively regulated Notch1. Compared with the control group, there was significantly

increased miR-449a expression in the miR-449a mimic group, and there was significantly decreased expression of Notch1, Jagged1, PCNA, MMP-2, MMP-9 and Bcl-2, increased Bax, reduced cell proliferation, increased G1-phase cell fraction, decreased S-phase cell fraction, an increased apoptosis rate, and decreased invasion ability in the miR-449a mimic group and DAPT group (all $P < 0.05$). However, the results in the miR-449a inhibitor group were the opposite of those in miR-449a mimic group (all $P < 0.05$). There was no significant difference in cell proliferation, apoptosis and invasion in the NC group and miR-449a inhibitor + DAPT group compared to the control group (all $P > 0.05$). miR-449a overexpression can inhibit Notch signaling pathway, thereby inhibiting the proliferation and invasion of papillary thyroid carcinoma cells and promoting cell apoptosis.

Introduction

Thyroid carcinoma is the leading cause of increasing morbidity and mortality of head and neck neoplasms, and 80% of patients with thyroid carcinoma have papillary thyroid carcinoma (PTC) (1). A study revealed that PTC has heterogeneous molecular characteristics and widely changeable clinical behavior during the development of the tumor as compared to other tumors in humans. Some PTCs are lethal clinically due to the tolerance to conventional radiotherapy and drug therapy in PTC (2).

The mammalian genome contains hundreds of microRNA (miRNA) and non-coding RNAs with a length of 18-25 nucleotides, regulating the expression of 30% of human genes (3), and a miRNA may function as a tumor suppressor by inhibiting the expression of an oncogene. In addition, tumor progression is promoted by reducing the expressions of certain tumor suppressors (4). Aberrant miRNA expression has been confirmed in the majority of diseases including all major cancers. However, only few human miRNAs, including miR-449 (1), miR-129-5p (5) and miR-146-5p (6), has been demonstrated to be aberrantly expressed in PTC. A study reported that miR-449 acts as a tumor suppressor by inducing cell senescence and apoptosis (7).

Notch is a multifunctional transmembrane receptor and can regulate the differentiation, development, proliferation

Correspondence to: Professor Yujie Hou, Department of Endocrinology, Second People's Hospital of Guilin, Diecai Road, Diecai, Guilin, Guangxi Zhuang Autonomous Region 541002, P.R. China
E-mail: houyujie2c9@163.com

Abbreviations: PTC, papillary thyroid carcinoma; miRNA, microRNA; NC, negative control; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; TBST, tris-buffered saline Tween; PI, propidium iodide

Key words: miR-449a, Notch signaling pathway, papillary thyroid carcinoma, proliferation, apoptosis, invasion

and survival of normal cells or cancer cells in various cases. Notch signaling transduction consists of four Notch receptors (Notch 1, 2, 3 and 4) and five ligands [Delta 1, 3, 4 and Jagged (Jag) 1 and 2] (8). The Notch signaling pathway has been revealed to contribute to the progression of several cancers, including the proliferation, invasion and apoptosis of cancer cells (9,10). Some studies have revealed that Notch1 and its ligand Jagged1 may play a key role in epithelial-mesenchymal transition and cancer stem cell regulation during the occurrence and development of a tumor, and that the alteration of Notch1 expression leads to the alteration of the Notch signaling pathway, which affects the expression of downstream Jagged1 (11-13). Many studies have revealed that the Notch signaling pathway has an impact on the proliferation, invasion and apoptosis of non-small cell lung cancer and pancreatic cancer cells, further affecting the expression of proliferation-related factor PCNA, invasion-related factors MMP-2, MMP-9 and apoptosis-related factor Bcl-2 (13-15). However, it is hard to interpret the specific mechanism of Notch signaling pathway in thyroid carcinoma. Bioinformatics prediction revealed that there is a target relationship between miR-449a and Notch1, and miR-449 plays a role in cancers by acting as a tumor suppressor (16). Therefore, it was speculated that miR-449a may suppress the Notch signaling pathway, inhibit the proliferation and invasion of PTC cells, and promote PTC cell apoptosis by targetedly downregulating Notch 1 expression.

Materials and methods

Cell culture. Human papillary thyroid carcinoma cell line TPC-1 (cat. no. JH-H1522; Shanghai Jihe Biotechnology Co. Ltd.) was cultured with RPMI-1640 medium containing 10% fetal bovine serum (FBS), 50 U/ml penicillin and 100 μ g/ml streptomycin (all from Gibco; Thermo Fisher Scientific, Inc.) in a 5% CO₂ cell incubator (model number: Thromo3111; Thermo Fisher Scientific, Inc.) at 37°C. The medium was renewed every day. Cells were passaged on 3-4 days. Well-grown cells in the logarithmic phase were collected for subsequent experiments.

Cell grouping and transfection. Human papillary thyroid carcinoma cell line TPC-1 in the logarithmic phase was seeded in 6-well plates at a density of 1x10⁵ cells/well and cultured with serum-free and double-antibody-free RPMI-1640 medium the day before transfection. Cells were divided into 6 groups: The control group (without any treatment), the negative control (NC) group (transfection with NC plasmid), the miR-449a mimic group (transfection with miR-449a mimic), the miR-449a inhibitor group (transfection with miR-449a inhibitor), the DAPT group (addition of 5 μ M DAPT), and the miR-449a inhibitor + DAPT group (transfection with miR-449a inhibitor and addition of DAPT). Transfection was performed strictly according to the instructions of the Lipofectamine 2000 reagent. A total of 8 μ l Lipofectamine 2000 (Thermo Fisher Scientific, Inc.) were mixed with 200 μ l phosphate-buffered saline (PBS) (Thermo Fisher Scientific, Inc.), standing for 5 min; 50 nmol/l miR-449a mimic, miR-449a inhibitor or NC plasmid dry powders (Shanghai GenePharma Co., Ltd.) were mixed with 200 μ l PBS, standing for 5 min. The two mixtures were mixed by slightly shaking, and then allowed to stand for

20 min at room temperature. Then 5 μ M DAPT and the aforementioned mixture were added to 6-well plates and mixed gently. The medium was replaced by the medium containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) after 8 h of transfection. After 48 h of transfection, the cells were collected for subsequent experiments.

Dual-luciferase reporter system. The binding site of miR-449a and Notch1 was analyzed through a bioinformatics prediction website (www.targetscan.org). Then the target relationship between miR-449a and Notch1 was verified by dual-luciferase reporter system. A dual-luciferase reporter gene vector of the target gene SP1 and mutant on the binding site of miR-449a and Notch1 were constructed: PGL3-Notch1 wt and PGL3-Notch1 mut. *Renilla* plasmid and two reporter plasmids were co-transfected with miR-449a plasmid and NC plasmid into 293T cells (Chinese Academy of Sciences Cell Bank, Shanghai, China). A dual luciferase reporter assay was carried out 24 h after cell transfection. Cells were lysed with 1X passive lysis buffer (Promega) and centrifuged at 12,000 x g for 1 min. The supernatant was collected. A dual-luciferase reporter kit (Promega Corp.) was used according to the instructions to assess luciferase activity. The lysed cell samples were pipetted into EP tubes. Every 10- μ l cell sample was mixed with 100 μ l firefly luciferase working solution to assess the firefly luciferase activity and then mixed with 100 μ l *Renilla* luciferase working solution to assess the *Renilla* luciferase activity. The relative luciferase activity was calculated as follows: Firefly luciferase activity/*Renilla* luciferase activity.

qRT-PCR. Total RNA of cells collected after transfection for 48 h was extracted using TRIzol (cat. no. 16096020; Thermo Fisher Scientific, Inc.) and Rapid Tissue Cellular miRNA Extraction Kit (cat. no. B1802; Harbin HaiGene Biotechnology Co., Ltd.) and reverse-transcribed into cDNA using TaqMan MicroRNA Assays Reverse Transcription Primer (Thermo Scientific Scientific, Inc.). SYBR[®] Premix Ex Taq[™] II kit (Xingzhi Biotechnology Co., Ltd., China) was used to carry out fluorescence quantitative polymerase chain reaction (PCR). The reaction solution was comprised of 25 μ l SYBR[®] Premix Ex Taq[™] II (2X), 2 μ l PCR forward primer, 2 μ l PCR reverse primer, 1 μ l ROX Reference Dye (50X), 4 μ l DNA templates, and 16 μ l ddH₂O. Fluorescence quantitative PCR was performed by ABI PRISM[®] 7300 system (Prism[®] 7300; Shanghai Kunke Instruments and Equipment Co., Ltd.). Reaction conditions were as follows: Pre-denaturation at 95°C for 10 min, 32 cycles of denaturation at 95°C for 15 sec and annealing at 60°C for 30 sec followed by extension at 72°C for 1 min. The 2^{- $\Delta\Delta$ Cq} method was used to calculate the relative expression of the target gene (17). The following formulas were used: Δ Cq=Cq_(target gene)-Cq_(GAPDH); $\Delta\Delta$ Cq= Δ Cq_(experimental group)- Δ Cq_(control group). U6 was used as the internal reference of miR-449a, and for other genes GAPDH was used as the internal reference. Primers are presented in Table I.

Western blotting. After transfection for 48 h, the cells were washed three times with precooled PBS. Total protein in cells was extracted using RIPA lysate containing PMSF (cat. no. R0010; Solarbio Life Sciences). Protein concentration was assessed by BCA kit (Thermo Fisher Scientific, Inc.), and deionized water

Table I. Primer sequences.

Gene	Sequence
miR-449a	F: 5'-GCTGGCAGTGTATTGTTA-3' R: 5'-GTGCAGGGTCCGAGGT-3'
Notch1	F: 5'-CAGCGAATCCGAOACTATG-3' R: 5'-CAGGCGTGTGTTCTCACAG-3'
Jagged1	F: 5'-AGTCACTGGCACGGTYGTAG-3' R: 5'-TCGCTGTATCTGTCCACCTG-3'
PCNA	F: 5'-GTGCAGAACTTGAAATGGAAAC-3' R: 5'-TTGAAGAGAGTGGAGTGGCT-3'
MMP-2	F: 5'-CAGGAGGAGAAGGCTGTGTT-3' R: 5'-AGGGTGCTGGCTGAGTAGAT-3'
MMP-9	F: 5'-AGAACCAATCTCACCGACAGG-3' R: 5'-CGACTCTCCACGCATCTCT-3'
Bcl-2	F: 5'-AACACCAGAATCAAGTGTGG-3' R: 5'-TCAGGTGGACCACAGGTGGC-3'
Bax	F: 5'-ACGGTITCATcCAGGATCGAGCC-3' R: 5'-AGGCGGTGAGGACTCCAGCC-3'
U6	F: 5'-CTCGCTTCGGCAGCACATATACT-3' R: 5'-ACGCTTCACGAATTTGCGTGTGTC-3'
GAPDH	F: 5'-GGGTGATGCTCGTGCTGAGTATGT-3' R: 5'-AAGAATGGGTGTTGCTGTTGAAGTC-3'

F, forward; R, reverse.

was used for the zero setting. The sample was mixed with loading buffer and boiled in a metal bath at 100°C for 10 min. Then 50 µg protein samples were added for sample application, and electrophoresis was performed for 3 h at a constant voltage of 70 V. Proteins were transferred to PVDF membranes (cat. no. ISEQ00010; EMD Millipore) by wet method with a constant current of 150 mA. The membranes were sealed with 5% skimmed milk powder at room temperature for 2 h. The milk was discarded, and the residual milk was washed off with Tris-buffered saline Tween (TBST). The membranes were incubated with primary antibodies rabbit anti-human Notch1 (product code ab194123; 1:5,000), Jagged1 (product code ab7771; 1:500), PCNA (product code ab92552; 1:5,000), MMP-2 (product code ab37150; 1:5,000), MMP-9 (product code ab73734; 1:5,000), Bax (product code ab32503; 1:1,000), Bcl-2 (product code ab32124; 1:1,000) and GAPDH (cat. no. ab22555; 1:2,000, all from Abcam) at 4°C overnight. Then the membranes were washed with TBST three times, for 6 min each time. The membrane was incubated with horseradish peroxidase-labeled goat anti-rabbit IgG antibody (1:5,000, Beijing Zhongshan Biotechnology Co., Ltd.) for 2 h. Then the membranes were washed with TBST three times, for 6 min each time, followed by immersing in Tris-buffered saline. The same volume of solution A (luminol) and B (peroxide) in an ECL fluorescent assay kit (BB-3501; BestBio, Shanghai, China) was mixed and added on the membrane drop wise. Imaging was performed by gel imager using a Bio-Rad image analysis system (Bio-Rad Laboratories, Inc.) and analyzed by ImageJ 2.0 software (National Institutes of Health). The relative protein content was calculated as follows: Gray value of the target protein band/gray value of the GAPDH band.

Cell proliferation detection by EdU. Cells in the logarithmic phase were seeded into a 24-well plate at a density of 4×10^3 cells/well and cultured to the normal growth phase. EdU was diluted using cell culture medium to prepare 50 µM EdU solutions. EdU solutions (100 µl) were added to each well, and reacted with medium for 2 h. The medium was then discarded. Cells were washed twice with PBS, for 5 min each time. Cell fixative was supplemented with PBS containing 4% paraformaldehyde and added into each well at 37°C for 30 min. Then the reaction mixture was pipetted. PBS was supplemented with 0.5% Triton X-100 to prepare fresh penetrating agent. Fresh penetrating agent (100 µl) was added to each well, followed by reaction on the shaking table at 37°C for 10 min. Then cells were washed with PBS for 5 min. 1X Apollo® staining solution (100 µl) was added, and the plate was coated with tin foil paper followed by reaction on a shaking table at 37°C for 30 min. Then the staining solution was discarded. Fresh penetrating agent (100 µl) was added to each well and reacted three times, each time for 10 min. Then the penetrating agent was discarded. After each reaction, cells were washed with methanol twice and PBS once, successively, for 5 min each time. The prepared 1X Hoechst33342 dye solution was stored in a dark place. 1X Hoechst33342 dye solution (100 µl) was added to each well, and the plate was coated with tin foil paper followed by reaction on the shaking table at 37°C for 30 min. Then the dye solution was discarded. Each well was washed three times with 100 µl PBS. Stained cells were observed under a fluorescence microscope. Five visual fields (200x) were selected randomly under an inverted microscope. EdU-stained cells (proliferative cells) and Hoechst33342 stained cells (total cells) were counted. The cell proliferation rate was calculated as follows: Cell proliferation rate = number of proliferative cells/number of total cells x 100%. The experiment was repeated three times.

Cell cycle and apoptosis detection by flow cytometry. After transfection for 48 h, cells were washed with PBS three times and centrifuged at 2,200 x g for 20 min. The supernatant was discarded. The cell concentration was adjusted to 1×10^5 cells/ml using PBS. Precooled 75% ethanol (1 ml) was added to the cells and placed at 4°C for 1 h. Then cells were centrifuged at 1,300 x g for 5 min and washed with PBS three times. RNase A (120 µl; Thermo Fisher Scientific, USA) was added to the cells in a dark place followed by a water bath at 37°C for 40 min. Cells were dyed with 500 µl propidium iodide (PI) (Sigma-Aldrich; Merck KGaA), mixed, and placed in a dark place at 4°C for 30 min. Red fluorescence at an excitation wavelength of 488 nm was recorded by flow cytometry (BeckmanCoulter) to detect the cell cycle.

After transfection for 48 h, cells were digested by EDTA-free trypsin (Thermo Fisher Scientific, Inc.) and collected to a flow tube. Cells were centrifuged at 2,200 x g for 30 min, and the supernatant was discarded. Cells were washed with precooled PBS three times and centrifuged at 2,200 x g for 20 min. The supernatant was discarded. HEPES buffer, Annexin-V-FITC and PI (50:1:2) were used to prepare an Annexin V-FITC/PI dye solution according to the instruction of Annexin-V-FITC apoptosis assays kit (Sigma, USA). Cells were mixed with 100 µl dye solution and incubated at room temperature for 15 min. Then cells were mixed with 1 ml HEPES buffer (Thermo Fisher Scientific, Inc.) by shaking.




Figure 1. Negative target regulation of miR-449a on Notch1. (A) Sequence of the binding site of miR-449a and Notch1 in the 3'-UTR region. (B) Luciferase activity detection by dual-luciferase reporter assay. * $P < 0.05$, compared with the NC group. Mut, mutational; Wt, wild-type; NC, negative control.

Cell apoptosis was detected at an excitation wavelength of 488 nm by flow cytometry.

Cell invasion detection by Transwell assay. Transwell chambers were placed into 96-well plates. The upper chamber of the Transwell chamber was coated with Matrigel diluent (1:8) and dried at room temperature. Cells were digested by trypsin and rinsed with PBS three times. Cells were re-suspended with RPMI-1640 medium at a density of 1×10^5 cells/ml. The Matrigel-coated (Qcbio Science & Technologies Co., Ltd.) upper chamber was supplemented with 300 μ l cell suspension. RPMI-1640 medium (500 μ l) containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) was added to the lower chamber. After 24 h of conventional culture, the Transwell chamber was removed, and unnecessary cells on the upper chamber were wiped off gently with cotton swabs. Cells were fixed with 4% paraformaldehyde (Beijing Leagene Biotechnology Co., Ltd.) for 20 min, dyed with 0.5% crystal violet solution (Beijing Solarbio Science & Technology Co., Ltd.) for 10 min, and washed with PBS three times. Imaging was performed in 5 visual fields (x200) that were randomly selected under an inverted microscope. The number of cells permeating the membrane were counted.

Statistical analysis. SPSS 21.0 (IBM Corp.) software was used to analyze the data. The measurement data were expressed as the mean \pm standard deviation. Comparison among groups was performed by one-way ANOVA in conjunction with Tukey's post hoc test for pairwise comparison. A P -value of < 0.05 was considered to be statistically significant.

Results

Negative target regulation of miR-449a on Notch1. A specific binding site of miR-449a and Notch1 was identified through analysis using bioinformatics prediction website microrna.org (<http://www.microrna.org/microrna/home.do>) (Fig. 1A). Results of the dual-luciferase reporter assay revealed that compared with the NC group, the luciferase activity of wild-type Notch1 was significantly reduced ($P < 0.05$), and




Figure 2. mRNA expression detection of miR-449a, Notch1 and Jagged1 by qRT-PCR. * $P < 0.05$, compared with the control group; # $P < 0.05$, compared with the NC group; * $P < 0.05$, compared with the miR-449a mimic group; # $P < 0.05$, compared with the miR-449a inhibitor group; @ $P < 0.05$, compared with the DAPT group. NC, negative control.

there was no significant difference in the luciferase activity of mutational-Notch1 in the miR-449a mimic group ($P > 0.05$) (Fig. 1B), indicating the negative target regulation of miR-449a on Notch1.

miR-449a, Notch1 and Jagged1 mRNA expression levels. The mRNA expression levels of miR-449a and Notch1, signaling pathway-related factors, were detected by qRT-PCR (Fig. 2). Compared to the control group, there was no significant difference in the expression of genes in the NC group ($P > 0.05$), however, the mRNA expression of Notch1 and Jagged1 in the miR-449a mimic group and DAPT group were significantly decreased (both $P < 0.05$). In addition, Notch1 and Jagged1 mRNA expression levels in the miR-449a inhibitor group were significantly increased (both $P < 0.05$). Compared with the miR-449a inhibitor group, Notch1 and Jagged1 mRNA expression levels in the miR-449a inhibitor + DAPT group were significantly decreased (both $P < 0.05$). miR-449a was significantly increased in miR-449a mimic group and




Figure 3. Notch1 and Jagged1 protein expression detection by western blotting. (A) Notch1 and Jagged1 protein bands. (B) Notch1 and Jagged1 protein expression. *P<0.05, compared with the control group; #P<0.05, compared with the NC group; &P<0.05, compared with the miR-449a mimic group; \$P<0.05, compared with the miR-449a inhibitor group; @P<0.05, compared with the DAPT group. NC, negative control.




Figure 4. Cell proliferation detection by EdU. (A) EdU staining (x100). (B) Cell proliferation. *P<0.05, compared with the control group; #P<0.05, compared with the NC group; &P<0.05, compared with the miR-449a mimic group; \$P<0.05, compared with the miR-449a inhibitor group; @P<0.05, compared with the DAPT group. NC, negative control.

significantly decreased in the miR-449a inhibitor group and miR-449a inhibitor + DAPT group (all P<0.05).

Notch1 and Jagged1 protein expression levels. Results of western blotting are presented in Fig. 3. Compared with the control group, there was no significant difference in the protein

expression levels of genes in the NC group (P>0.05), however, the protein expression levels of Notch1 and Jagged1 in the miR-449a mimic group and DAPT group were significantly decreased (both P<0.05). In addition, Notch1 and Jagged1 protein expression levels in the miR-449a inhibitor group were significantly increased (both P<0.05). Compared with




Figure 5. Cell cycle detection by flow cytometry. (A) The cell cycle. (B) Cell cycle distribution. *P<0.05, compared with the control group; #P<0.05, compared with the NC group; &P<0.05, compared with the miR-449a mimic group; \$P<0.05, compared with the miR-449a inhibitor group; @P<0.05, compared with the DAPT group. NC, negative control.

the miR-449a inhibitor group, Notch1 and Jagged1 protein expression levels in the miR-449a inhibitor + DAPT group were significantly decreased (both P<0.05).

Cell proliferation. Results of EdU are presented in Fig. 4. Compared with the control group, there was no significant difference in the EdU-positive cell rate in the NC group (P>0.05), however, the EdU-positive cell rate in the miR-449a mimic group and DAPT group was significantly lower (both P<0.05). In addition, the EdU-positive cell rate in the miR-449a

inhibitor group was significantly higher (P<0.05). Compared with miR-449a inhibitor group, the EdU-positive cell rate in the miR-449a inhibitor + DAPT group was significantly decreased (P<0.05).

Cell cycle. Results of flow cytometry are presented in Fig. 5. Compared with the control group, there was no significant difference in each phase in the NC group and miR-449a inhibitor + DAPT group (both P>0.05); there was a significant increase of cells in the G1 phase and a significant





Figure 6. Apoptosis detection by flow cytometry. (A) Flow cytometric scatter plot. (B) Apoptosis rate. *P<0.05, compared with the control group; #P<0.05, compared with the NC group; &P<0.05, compared with the miR-449a mimic group; &P<0.05, compared with the miR-449a inhibitor group; @P<0.05, compared with the DAPT group. NC, negative control; PI, propidium iodide.

decrease of cells in the S phase in the miR-449a mimic group and DAPT group (both P<0.05). There was also a significant decrease of cells in the G1 phase and a significant increase of cells in the S phase in the miR-449a inhibitor group (both P<0.05). Compared with miR-449a inhibitor group, there was a significant increase of cells in the G1 phase and a significant decrease of cells in the S phase in the miR-449a inhibitor + DAPT group (both P<0.05). There

was no significant difference in cells in the G2 phase among groups (P>0.05).

Apoptosis. Apoptosis was detected by flow cytometry (Fig. 6). Compared with the control group, there was no significant difference in apoptosis in the NC group and miR-449a inhibitor + DAPT group (both P>0.05), however, apoptosis was significantly increased in the miR-449a mimic group and




Figure 7. Cell invasion detection by Transwell assay (A) Cell invasion detection by Transwell assay (x200). (B) Number of invasive cells. *P<0.05, compared with the control group; #P<0.05, compared with the NC group; &P<0.05, compared with the miR-449a mimic group; §P<0.05, compared with the miR-449a inhibitor group; @P<0.05, compared with the DAPT group. NC, negative control.

DAPT group (both P<0.05), and significantly decreased in the miR-449a inhibitor group (P<0.05).

Cell invasion. Cell invasion was detected by Transwell assay (Fig. 7). Compared with the control group, there was no significant difference in the number of invasive cells in the NC group and the miR-449a inhibitor + DAPT group (both P>0.05); the number of invasive cells was significantly decreased in the miR-449a mimic group and DAPT group (both P<0.05), and significantly increased in the miR-449a inhibitor group (P<0.05). Compared with the miR-449a inhibitor group, the number of invasive cells was significantly decreased in the miR-449a inhibitor + DAPT group (P<0.05).

mRNA expression of PCNA, MMP-2, MMP-9, Bcl-2 and Bax. The mRNA expression of proliferation-related factor PCNA, invasion-related factors MMP-2, MMP-9 and apoptosis-related factors Bcl-2 and Bax were detected by qRT-PCR (Fig. 8). Compared with the control group, there was no significant difference in the expression of these genes in the NC group and the miR-449a inhibitor + DAPT group (all P>0.05), however, there was a significant decrease in the mRNA expression of PCNA, MMP-2, MMP-9 and Bcl-2 and an increase of Bax mRNA expression in the miR-449a mimic group and DAPT group (all P<0.05). In addition, there was a significant increase in the mRNA expression of PCNA, MMP-2, MMP-9 and Bcl-2 and a decrease of Bax mRNA expression in the miR-449a inhibitor group (all P<0.05). Compared with the miR-449a inhibitor group, there was a significant decrease in the mRNA expression of PCNA, MMP-2, MMP-9 and Bcl-2 and increase of Bax mRNA expression in miR-449a inhibitor + DAPT group (all P<0.05).

Protein expression of PCNA, MMP-2, MMP-9, Bcl-2 and Bax. The results of the western blotting are presented in Fig. 9. Compared with the control group, there was no significant




Figure 8. PCNA, MMP-2, MMP-9, Bax and Bcl-2 mRNA expression detection by qRT-PCR. *P<0.05, compared with the control group; #P<0.05, compared with the NC group; &P<0.05, compared with the miR-449a mimic group; §P<0.05, compared with the miR-449a inhibitor group; @P<0.05, compared with the DAPT group. NC, negative control.

difference in the expression of these proteins in the NC group and miR-449a inhibitor + DAPT group (all P>0.05), however, there was a significant decrease in the protein expression of PCNA, MMP-2, MMP-9 and Bcl-2 and an increase of Bax protein expression in the miR-449a mimic group and DAPT group (all P<0.05). In addition, there was a significant increase in the protein expression of PCNA, MMP-2, MMP-9 and Bcl-2 and a decrease of Bax protein expression in the miR-449a inhibitor group (all P<0.05). Compared with the miR-449a inhibitor group, there was a significant decrease in the protein expression of PCNA, MMP-2, MMP-9 and Bcl-2 and an increase of Bax protein expression in the miR-449a inhibitor + DAPT group (all P<0.05).




Figure 9. PCNA, MMP-2, MMP-9, Bax and Bcl-2 protein expression. (A) Protein bands. (B) PCNA, MMP-2, MMP-9, Bax and Bcl-2 protein expression. * $P < 0.05$, compared with the control group; # $P < 0.05$, compared with the NC group; & $P < 0.05$, compared with the miR-449a mimic group; \$ $P < 0.05$, compared with the miR-449a inhibitor group; @ $P < 0.05$, compared with the DAPT group. NC, negative control.

Discussion

Thyroid carcinoma is one of the most common malignant tumors in the head and neck, and PTC is the most common cancer among thyroid carcinomas, accounting for about 80%. The latest clinical data indicate that the incidence rate of thyroid carcinoma is on the rise worldwide (18). PTC has been revealed to be accompanied by distant lymphatic metastasis when diagnosed, due to the strong invasive ability of PTC cells and unapparent symptoms at the early stage. It is hard to trace the pathogenesis of PTC. Therefore, it is urgent to explore the molecular mechanism in the development of PTC and to develop broad-spectrum molecular targets and therapeutic drugs.

The downregulation of miR-449 has been observed in various human malignant tumors including lung cancer (19), gastric cancer (20) and colon cancer stem cells (21). The Notch receptor is a decisive factor of cell fate during the process of normal cell development (22,23). The Notch signaling pathway as an important mechanism determining cell fate plays a vital role in the regulation of cell differentiation and development (21). The Notch signaling pathway also plays an important role in cell proliferation and apoptosis (24-26). Aberrantly high-expression of Notch receptor and its ligands in cancer cells has been confirmed in various cancers (27,28).

It has been confirmed in some literature that Notch1 expression is increased in PTC and can promote downstream Jagged1 expression by activating the Notch signaling pathway, affecting the apoptosis, proliferation and invasion of PTC cells (29). In the present study, the Notch signaling pathway inhibitor DAPT was used to treat thyroid carcinoma cells TPC-1. It was revealed that there was significantly decreased expression of Notch1 and Jagged1, proliferation-related factor PCNA, invasion-related factors MMP-2, MMP-9 and apoptosis inhibitor Bcl-2 expression in cells, increased expression of apoptosis promoter Bax, decreased cell proliferation, blocked cell cycle progression, an increased apoptosis rate, and decreased cell invasion. The results revealed that the inhibition of the Notch signaling pathway suppressed the proliferation and invasion of PTC cells and

promoted their apoptosis, which was consistent with previous research. To further explore the regulatory mechanism of the upstream Notch signaling pathway, it was predicted through a bioinformatics prediction website that there was a target relationship between Notch1 and miR-449. A previous study also indicated that miR-449 had an inhibitory effect on a variety of cancers (30). By dual-luciferase reporter assay, the negative regulation of miR-449 on Notch1 was also confirmed. TPC-1 cells were transfected with miR-449 mimic, miR-449 inhibitor and miR-449 inhibitor + DAPT, and the results revealed that miR-449 overexpression inhibited the proliferation and invasion of PTC cells and promoted their apoptosis. miR-449 inhibited the Notch signaling pathway by targetedly inhibiting Notch1 expression, which downregulated Jagged1 expression, inhibited the proliferation and invasion of PTC cells, and promoted their apoptosis. Moreover, the inhibition of the Notch signaling pathway recovered the promotion of PTC progression induced by miR-449 silencing. In the present study, the downregulation of miR-449 expression was detected in TPC-1 cells.

In the present study, it was confirmed that miR-449a mediated the Notch signaling pathway by targeting Notch1 to inhibit PTC progression. The underlying mechanism of PTC was further elucidated, which established the theoretical basis for PTC treatment in clinical practice. In addition, mice experiments are required to verify the aforementioned results. However, the relationship between miR-449a and PTC, the molecular mechanism of the miR-449a downstream Notch1 gene which affects PTC, and the targeted regulatory network of miR-449a in PTC are not entirely clear yet.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Affiliated Hospital of Guilin Medical University (no. 20170109-7).

Availability of data and materials

The analysed data sets generated during the study are available from the corresponding author on reasonable request.

Authors' contributions

YH contributed to all the tasks, including data collection, data analysis, experimental operation, manuscript design and writing. FF and RY made substantial contributions to the revision of the manuscript, the design of the study, and interpretation of data for this study. All authors provided final approval of the version to be published.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Li Z, Huang X, Xu J, Su Q, Zhao J and Ma J: miR-449 over-expression inhibits papillary thyroid carcinoma cell growth by targeting RET kinase- β -catenin signaling pathway. *Int J Oncol* 49: 1629-1637, 2016.
- Wu D, Liu J, Chen J, He H, Ma H and Lv X: miR-449a suppresses tumor growth, migration, and invasion in non-small cell lung cancer by targeting a HMGB1-Mediated NF- κ B signaling pathway. *Oncol Res* 27: 227-235, 2019.
- Zhang YL, Li XB, Hou YX, Fang NZ, You JC and Zhou QH: The lncRNA XIST exhibits oncogenic properties via regulation of miR-449a and Bcl-2 in human non-small cell lung. *Acta Pharmacol Sin* 38: 371-381, 2017.
- Ji C, Xu Q, Guo L, Wang X, Ren Y, Zhang H, Zhu W, Ming Z, Yuan Y, Ren X, *et al*: eEF-2 Kinase-targeted miR-449b confers radiation sensitivity to cancer cells. *Cancer Lett* 418: 64-74, 2018.
- Zhang H, Cai Y, Zheng L, Zhang Z, Lin X and Jiang N: Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129-5p/KLK7 expression. *J Cell Physiol* 233: 6638-6648, 2018.
- Geraldo MV, Fuziwara CS, Friguglietti CU, Costa RB, Kulcsar MA, Yamashita AS and Kimura ET: MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: A case report. *Arq Bras Endocrinol Metabol* 56: 552-557, 2012.
- Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, Krogh A, Bardram L, Hother C, Grønbaek K, Federspiel B, Lund AH and Friis-Hansen L: miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. *Mol Cancer* 10: 29, 2011.
- Kim HJ, Kim MJ, Kim A, Jung CW, Park S, Koh JS and Myung JK: The role of notch1 signaling in anaplastic thyroid carcinoma. *Cancer Res Treat* 49: 509-517, 2017.
- Cao YW, Wan GX, Sun JP, Cui XB, Hu JM, Liang WH, Zheng YQ, Li WQ and Li F: Implications of the Notch1-Snail/Slug-epithelial to mesenchymal transition axis for lymph node metastasis in infiltrating ductal carcinoma. *Kaohsiung J Med Sci* 31: 70-76, 2015.
- Gopalakrishnan N, Sivasithamparam ND and Devaraj H: Synergistic association of Notch and NF κ B signaling and role of Notch signaling in modulating epithelial to mesenchymal transition in colorectal adenocarcinoma. *Biochimie* 107: 310-318, 2014.
- Wang Z, Li Y, Kong D and Sarkar FH: The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. *Curr Drug Targets* 11: 745-751, 2010.
- Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L and Sarkar FH: Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. *Cancer Lett* 307: 26-36, 2011.
- Hu KF, Kong XY, Zhong MC, Wan HY, Lin N and Pei XH: Brucine inhibits bone metastasis of breast cancer cells by suppressing Jagged1/Notch1 signaling pathways. *Chin J Integr Med* 23: 110-116, 2017.
- Yang Q, Cao X, Tao G, Zhou F, Zhao P, Shen Y and Chen X: Effects of FOXJ2 on TGF- β 1-induced epithelial-mesenchymal transition through Notch signaling pathway in non-small lung cancer. *Cell Biol Int* 41: 79-83, 2017.
- Bi YL, Min M, Shen W and Liu Y: Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity. *Tumour Biol* 37: 15145-15155, 2016.
- Cheng J, Wu Q, Lv R, Huang L, Xu B, Wang X, Chen A and He F: MicroRNA-449a inhibition protects H9C2 cells against hypoxia/reoxygenation-induced injury by targeting the Notch-1 signaling pathway. *Cell Physiol Biochem* 46: 2587-2600, 2018.
- Livak K and Schmittgen T: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
- Hu J, Li C, Liu C, Zhao S, Wang Y and Fu Z: Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC. *Cancer Biomark* 18: 87-94, 2017.
- Luo W, Huang B, Li Z, Li H, Sun L, Zhang Q, Qiu X and Wang E: MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. *PLoS One* 8: e64759, 2013.
- Yang X, Wang HL, Liang HW, Liang L, Wen DY, Zhang R, Chen G and Wei DM: Clinical significance of microRNA-449a in hepatocellular carcinoma with microarray data mining together with initial bioinformatics analysis. *Exp Ther Med* 15: 3247-3258, 2018.
- Li F, Liang J and Bai L: MicroRNA-449a functions as a tumor suppressor in pancreatic cancer by the epigenetic regulation of ATDC expression. *Biomed Pharmacother* 103: 782-789, 2018.
- Aster JC, Pear WS and Blacklow SC: The varied roles of notch in cancer. *Annu Rev Pathol* 12: 245-275, 2017.
- Rong C, Feng Y and Ye Z: Notch is a critical regulator in cervical cancer by regulating Numb splicing. *Oncol Lett* 13: 2465-2470, 2017.
- Yang X, Duan B and Zhou X: Long non-coding RNA FOXD2-AS1 functions as a tumor promoter in colorectal cancer by regulating EMT and Notch signaling pathway. *Eur Rev Med Pharmacol Sci* 21: 3586-3591, 2017.
- Zhou Y, An Q, Guo RX, Qiao YH, Li LX, Zhang XY and Zhao XL: miR424-5p functions as an anti-oncogene in cervical cancer cell growth by targeting KDM5B via the Notch signaling pathway. *Life Sci* 171: 9-15, 2017.
- Shen Q, Cohen B, Zheng W, Rahbar R, Martin B, Murakami K, Lamorte S, Thompson P, Berman H, Zúñiga-Pflücker JC, *et al*: Notch shapes the innate immunophenotype in breast cancer. *Cancer Discov* 7: 1320-1335, 2017.
- Li C, Liu S, Yan R, Han N, Wong KK and Li L: CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. *Theranostics* 7: 67-80, 2017.
- Cai H, Yao J, An Y, Chen X, Chen W, Wu D, Luo B, Yang Y, Jiang Y, Sun D and He X: LncRNA HOTAIR acts a competing endogenous RNA to control the expression of notch3 via sponging miR-613 in pancreatic cancer. *Oncotarget* 8: 32905-32917, 2017.
- Jung CW, Kong JS, Seol H, Park S, Koh JS, Lee SS, Kim MJ, Choi IJ and Myung JK: Expression of activated Notch1 and Hey1 in papillary thyroid carcinoma. *Histopathology* 70: 301-308, 2017.
- Sun J, Shi R, Zhao S, Li X, Lu S, Bu H, Ma X and Su C: E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle. *J Exp Clin Cancer Res* 36: 40, 2017.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.